Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FcRn in retinal pigment epithelium and age-related macular degeneration
NL-OMON32041Recruiting
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Jun 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab and ranibizumab in age-related macular degeneration (AMD) (2 arms), sponsored by Het Oogziekenhuis Rotterdam. Started Jun 2009; status: recruiting.
02
Drugs
bevacizumabranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON32041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32041.